(Q36790707)

16 August 2017

1 reference

title

Serum IGF-I levels in the diagnosis and monitoring of acromegaly (English)

1 reference

16 August 2017

Brooke AM

1

1 reference

16 August 2017

Drake WM

series ordinal

2

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

10

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

173-179

1 reference

Decreased IGF-I bioavailability after ethanol abuse in alcoholics: partial restitution after short-term abstinence

16 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11102-007-0036-8

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

21 January 2018

1 reference

12 December 2020

Quantitative measurement of IGF-I and its use in diagnosing and monitoring treatment of disorders of growth hormone secretion

1 reference

12 December 2020

Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels

1 reference

12 December 2020

Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly

1 reference

12 December 2020

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

1 reference

12 December 2020

Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion

1 reference

12 December 2020

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly

1 reference

12 December 2020

Remission criteria for the follow-up of patients with acromegaly

1 reference

12 December 2020

Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults

1 reference

12 December 2020

Current treatment guidelines for acromegaly

1 reference

12 December 2020

Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia

1 reference

12 December 2020

Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly

1 reference

12 December 2020

Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly

1 reference

12 December 2020

Insulin-like growth factors in the fed and fasted states.

1 reference

12 December 2020

Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy

1 reference

12 December 2020

Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors

1 reference

12 December 2020

Current concepts in the biochemical assessment of the patient with acromegaly

1 reference

12 December 2020

Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society

1 reference

12 December 2020

Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial

1 reference

12 December 2020

Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.

1 reference

12 December 2020

Growth hormone secretion in recently operated acromegalic patients

1 reference

12 December 2020

The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.

1 reference

12 December 2020

Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly

1 reference

12 December 2020

Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH

1 reference

12 December 2020

Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.

1 reference

12 December 2020

A nationwide survey of mortality in acromegaly

1 reference

12 December 2020

Factors influencing mortality in acromegaly

1 reference

12 December 2020

Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults

1 reference

12 December 2020

Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'

1 reference

12 December 2020

The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients

1 reference

12 December 2020

1 reference

12 December 2020

Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.

1 reference

12 December 2020

Criteria for cure of acromegaly: a consensus statement

1 reference

12 December 2020

IGFBP‐3 is a poor parameter for assessment of clinical activity in acromegaly

1 reference

12 December 2020

Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone an

1 reference

12 December 2020

Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.

1 reference

12 December 2020

Insulin-like growth factors and their binding proteins: biological actions

1 reference

12 December 2020

Guidelines for acromegaly management

1 reference

12 December 2020

Metabolic functions of liver-derived (endocrine) insulin-like growth factor I.

1 reference

12 December 2020

Inter-relations between growth hormone, insulin, insulin-like growth factor-l (IGF-I), IGF-binding protein-1 (IGFBP-1) and sex hormone-binding globulin in acromegaly

1 reference

12 December 2020

Mortality in acromegaly

1 reference

12 December 2020

A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue

1 reference

12 December 2020

The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly

1 reference

12 December 2020

Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up

1 reference

12 December 2020

Hypothalamic dysfunction in "cured" acromegaly is treatment modality dependent

1 reference

12 December 2020

Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements

1 reference

12 December 2020

Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.

1 reference

12 December 2020

Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement

1 reference

12 December 2020

Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.

1 reference

12 December 2020

Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria

1 reference

12 December 2020

Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement

1 reference

12 December 2020

1 reference

12 December 2020

Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency

1 reference

12 December 2020

Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly

1 reference

12 December 2020

Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly

1 reference

12 December 2020

Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.

1 reference

12 December 2020

Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance

1 reference

12 December 2020

An audit of outcome of treatment in acromegaly.

1 reference

12 December 2020

Evaluation of Acromegaly by Radioimmunoassay of Somatomedin-C

1 reference

12 December 2020

6 Factors controlling blood concentration of somatomedin C

1 reference

12 December 2020

Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.

1 reference

12 December 2020

10.1007/S11102-007-0036-8

Identifiers

DOI

1 reference

16 August 2017

1 reference